secwatch.observer — SEC 8-K summary
======================================

Issuer:     CURIS INC (CRIS)
CIK:        0001108205
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001108205-22-000022
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curis Q3 net loss $13.3M, cuts ~30% of workforce to focus on emavusertib, cash runway into 2025
--------------------------------------------------------------------------------

- Net loss of $13.3M ($0.14/shr) vs $11.1M ($0.12/shr) in Q3 2021; revenues $2.8M.
- Plan to reduce workforce by ~30% and reallocate resources to emavusertib pipeline.
- Cash & equivalents $98.7M as of Sep 30; expects cash runway into 2025.
- Updated TakeAim Leukemia data for emavusertib to be presented at ASH 2022 (Dec 10-13).
- FDA has allowed enrollment to resume in TakeAim Lymphoma and monotherapy dose finding of TakeAim Leukemia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1108205/000110820522000022/0001108205-22-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1108205/000110820522000022/cris-20221109.htm
  HTML page:      https://secwatch.observer/filing/0001108205-22-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer